These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26634942)

  • 1. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M; Labrie F; Archer DF; Zerhouni J; Côté I; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Moyneur E; Balser J
    Gynecol Endocrinol; 2016; 32(3):240-5. PubMed ID: 26634942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF; Labrie F; Montesino M; Martel C
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
    Archer DF; Labrie F; Bouchard C; Portman DJ; Koltun W; Cusan L; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
    Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F; Montesino M; Archer DF; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
    Climacteric; 2015; 18(6):817-25. PubMed ID: 26517756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C; Labrie F; Archer DF; Portman DJ; Koltun W; Elfassi É; Grainger DA; Ayotte N; Cooper TA; Martens M; Waldbaum AS; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
    Climacteric; 2015; 18(4):590-607. PubMed ID: 25511551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F; Archer DF; Martel C; Vaillancourt M; Montesino M
    Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
    Archer DF
    J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA
    Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
    Portman DJ; Goldstein SR; Kagan R
    Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
    Labrie F; Archer DF; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Climacteric; 2011 Apr; 14(2):282-8. PubMed ID: 21244215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
    Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
    Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
    Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M; Davis SR
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.